RxDoctor Payments DataLook up a doctor →

Emil Valle, MD

Gastroenterology · Reston, VANPI 1497711238

Payments from drug & device makers

$188,003in general payments, 2019–2025

Across 720 payments — averaging $261.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$115K
  • Bristol Myers Squibb$61K
  • AbbVie$3K
  • Johnson & Johnson$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$962
  • plus $5K from 40 others
$7,977in research payments, 2019–2025

Across 9 payments — averaging $886.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$8K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly22$114,528
Bristol Myers Squibb63$61,380
AbbVie(2 entities)229$3,243
Johnson & Johnson(2 entities)54$1,448
Takeda Pharmaceuticals U.S.A., Inc.73$1,103
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC61$962
Pfizer46$735
Gilead27$568
Boston Scientific7$567
QOL Medical, LLC17$377
Regeneron Healthcare Solutions, Inc.15$349
Sanofi13$291
E.r. Squibb & Sons, L.L.C.2$229
Medtronic2$222
Ipsen Biopharmaceuticals, Inc8$173
Lilly USA, LLC8$173
Celltrion USA Inc.6$145
Olympus America Inc.2$140
Nestle Healthcare Nutrition Inc.7$126
Phathom Pharmaceuticals, Inc.7$121
Romark Laboratories, LC3$111
Ardelyx, Inc.4$92
Daiichi Sankyo Inc.4$82
Ironwood Pharmaceuticals, Inc5$82
Ferring Pharmaceuticals Inc.4$75
Madrigal Pharmaceuticals3$62
Aimmune Therapeutics, Inc.2$55
Novo Nordisk2$52
Alnylam Pharmaceuticals Inc.3$51
ERBE USA Inc1$50
UCB, Inc.2$40
Intercept Pharmaceuticals, Inc.2$40
Vivus LLC2$38
Covidien LP1$33
Redhill Biopharma Inc.2$33
Pharmacosmos Therapeutics Inc.1$31
Vibrant Gastro, Inc.1$27
Fresenius Kabi USA, LLC1$27
Amgen1$26
Enterra Medical, Inc.1$25
Biocon Biologics Inc1$20
Endo Pharmaceuticals Inc.1$17
Echosens North America, Inc.1$16
Braintree Laboratories, Inc.1$15
Shire North American Group Inc1$13
Merck1$12

How this compares

$188,003 in reported general payments places this provider in the 90th percentile of 473 gastroenterology providers in Virginia.

See all gastroenterology providers in Virginia →

Medicare billing

Part B allowed, 2024
$292,944
Medicare patients
531
Services billed
7,866

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other gastroenterology in Reston

See the full list for Virginia →

Where these figures come from

Is this you, or does something look wrong? →